{"DataElement":{"publicId":"2789518","version":"1","preferredName":"Hormone Refractory Prostate Carcinoma Therapy Current Clinical Trial Period Administration Date","preferredDefinition":"the date of first therapy for hormone refractory prostate cancer (HRPC) administered during this reporting period.","longName":"H_R_P_TX_C_C_ADM_DT","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2787941","version":"1","preferredName":"Hormone Refractory Prostate Carcinoma Therapy Current Clinical Trial Period Administration","preferredDefinition":"information relating to the action of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process for hormone refractory (not responding to treatment) prostate cancer administered during the current report period (Clinical Trial Period; a possibly repeating collection of consecutive days that define the length of a Study Segment).","longName":"H_R_PRS_TX_C_CTP_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2425590","version":"1","preferredName":"Hormone Refractory Prostate Carcinoma","preferredDefinition":"Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various endocrine glands and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects.:Refractory; not responding to treatment.:Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002","longName":"C2315:C38014:C4863","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hormone","conceptCode":"C2315","definition":"Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various endocrine glands and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Refractory","conceptCode":"C38014","definition":"Not responding to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"049B5946-27C4-2FE1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-11-02","modifiedBy":"ONEDATA","dateModified":"2005-11-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2787939","version":"1","preferredName":"Therapy Current Clinical Trial Period Administration","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:Occurring in or belonging to the present time.:A possibly-repeating collection of consecutive days that define the length of a Study Segment:The act of administration.","longName":"C15368:C25471:C71737:C25409","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Current","conceptCode":"C25471","definition":"Occurring in or belonging to the present time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Clinical Trial Period","conceptCode":"C71737","definition":"A possibly-repeating collection of consecutive days that define the length of a Study Segment","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administration","conceptCode":"C25409","definition":"The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57F735E1-4310-4EBC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-28","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-09-28","modifiedBy":"ONEDATA","dateModified":"2008-09-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57F73AE6-4368-5168-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-28","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-09-28","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2018550","version":"1","preferredName":"Date","preferredDefinition":"The date on which an observation was made or an event occurred.","longName":"DT","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"DATE","minLength":null,"maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"format":"MM/DD/YYYY","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008561","version":"1","preferredName":"Occurrences","preferredDefinition":"dates, times, and durations.","longName":"OCURS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B53BD1AB-090B-398B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2233081","version":"1","preferredName":"Date","preferredDefinition":"a particular day specified as the time something has, or will, happen.","longName":"C25164","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Date","conceptCode":"C25164","definition":"The particular day, month and year an event has happened or will happen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F90B5E56-BB15-0F45-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-09","modifiedBy":"ONEDATA","dateModified":"2005-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"B54EF112-5457-674A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-28","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-28","modifiedBy":"ZHWENDY","dateModified":"2023-12-12","changeDescription":"8/3/17 tt added Diagnosis CSI. 6/20/17 jk transferred to NCI Standards per confirmation by Brian Campbell as part of Round 5 finalization task, added reg status.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811910","version":"1","longName":"Prostate","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CRF Text","type":"Preferred Question Text","description":"Date of first therapy for hormone refractory prostate cancer this reporting period","url":null,"context":"CTEP"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"5807FB83-D579-35D7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-09-29","modifiedBy":"SHIDED","dateModified":"2008-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}